It is a modular urinalysis workflow launched by DIRUI, which can meet the realistic needs of clinical laboratories for automated and high-throughput urine testing.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

LumiraDx on Tuesday reported an 82 percent year-over-year decrease in first quarter revenues due to falling demand for COVID-19 testing.

According to the report of "The Developments and Trends of China's Medical Device Industry" released by Roland Berger, a world leading management consultancy, the Chinese medical device market exceeded 900 billion yuan in 2022. It is projected to exceed 2.2 trillion CNY (about 320 billion USD) by 2030, making China potentially the largest medical device market globally.

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today reported financial results for the first quarter ended March 31, 2023.

A French team led by investigators at Institut Cochin in Paris has received €1.5 million ($1.7 million) in EU funding to develop biomarkers for endometriosis, a condition where tissue similar to the lining of a woman's uterus grows outside of it.

Shanghai Kirgen, a leading domestic manufacturer of high-end laboratory consumables and new materials, has just announced that it has completed a new round of financing of nearly 100 million Yuan.

OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced its financial results for the three months ended March 31, 2023.

Revvity, Inc., today reported financial results for the first quarter ended April 2, 2023.

On May 8, Singlera Genomics announced that its self-developed PDACatch test, a novel DNA methylation-based liquid biopsy test for detecting pancreatic cancer in high-risk populations, has been granted Breakthrough Medical Device designation by FDA.

Cue Health Inc., a healthcare technology company, today reported financial results for the first quarter 2023.

Siemens Healthineers AG today announces its results for the second quarter, ending March 31, of fiscal year 2023.